Connecting Patients to Clinical Trials

Developing innovative technologies and media for facilitating patient recruitment

TrialX enables...


such as Cinda to find trials for herself and her loved ones

Search Trials


such as Jennifer to complete her clinical trial recruitment on time

Upload Your Trial


such as the Cleveland Clinic to create a centralized trial listing and recruitment tool

Learn More


such as the MMRF to create awareness for research and trials

Learn More

Why customers love TrialX.

Innovative Technology

Developed using an award winning semantic technology that matches patients to trials using their full-clinical record and clinical trial inclusion/exclusion criteria. Recently, we developed another novel interactive question/answering technology (winner of the 2011 NCI/Health 2.0 Developer Challenge) that guides and connects patients to research site using live calls

Great User Experience

At TrialX, we develop tools that we'd like to use. We continually refine the user interface and the flow to make it even easier for our customers to do their tasks effectively.

Customer Service

We Listen. We listen to what our customers say and often we fix/add features even before they tell us. The secret sauce of our awesome customer service is that we also "listen" to DATA. We mine access logs, error logs to solve problems before they arise (sort of like the Minory Report!)

I have been very pleased with the recruitment effort of TrialX for my research studies. They have been very diligent in finding qualified subjects in a reasonable time frame. I would definitely recommend their services to clinical research sites.

Dr. Arthur Waldbaum MD
  • Janssen Biotech recently announced that it’s enrolling newly diagnosed multiple myeloma patients that aren’t eligible for a stem cell transplant.  The majority of ineligible transplant patients are older, but younger patients that are too sick to transplant can join the study, too. Here are the details, courtesy Pharmaceutical Business Janssen to start phase III […]
  • In 2012, researchers became excited about the possibility that a drug used to treat thyroid, liver and kidney cancer, sorafenib (Nexavar), might work on multiple myeloma, too.  I hadn’t heard much about it–until last week. Here are the results of yet another laboratory study, published Friday on the resource site: Two death pathways induced […]
  • Yesterday I introduced you to Don and Joan Hamilton.  Don was  diagnosed with multiple myeloma in 2008.  Joan is his caregiver and advocate.  We have emailed back and forth regularly for years.  Joan has been kind enough to allow me to tell Don’s multiple myeloma story.  It’s a cautionary tail I felt was important to […]
  • Joan Hamilton started emailing me years ago.  A devoted caregiver to her husband and multiple myeloma survivor, Don, at first Joan asked me a lot of questions about myeloma therapy and side effects.  But as time went on, Joan would email me more often, sharing things about her family and friends. For the past two […]
  • Following an online mix-up, I was able to review  results from last week’s SPEP test, the first since I started using Pomalyst (pomalidomide).  Very encouraging! My M-spike was 0.7 and slowly rising when I switched from RVD (Revlimid, Velcade and dexamethasone) to Pomalyst three weeks ago.  I completed my first 21 day cycle Saturday.  The […]
  • Oops!  I noticed this morning that our server was down.  Not sure how long; site was working last evening. I’m not good with the technical stuff.  Sort of like myeloma genetics; I’m a writer, not a math or science guy.  I had a tech volunteer for a time.  Robb had a degree in internet marketing.  […]
  • Major League Baseball’s annual All Star Game was played last night at Target Field in Minneapolis.  My dear friend, Karl Vollstedt, was a huge Minnesota Twins fan.  As I leaned over to pick up the phone to congratulate him and chat during the game, I was jolted back to reality: Karl died in April. For […]
  • There is ligh [...]
  • Is it time for a new multiple myeloma staging system?  If you think about it, it doesn’t really matter what stage a patient is at diagnosis; RVD works in close to 100% of patients, regardless of how they’re staged. Apparently some Japanese researchers think so: New Staging System Viable for Myeloma Treated With Novel Therapies […]
  • When I was first diagnosed back in April, 2007, I was told by my Mayo Clinic specialist that I had no concerning genetic prognostic indicators.  In other words, I was a low risk multiple myeloma patient.  But this spring I learned that had changed. Sometime between 2007 and 2011, my myeloma showed a significant shift.  […]
  • Here’s an excerpt from an interesting and comprehensive article from the July edition of Clinical Oncology News,  How I Manage: Evolving Role of Autologous Transplantation in Multiple Myeloma.   It features the views of myeloma specialist, Sagar Lonial, with the Winship Cancer Institute at Emory University in Atlanta: There is some discussion that, perhaps, patients […]
  • Joyce from Minnesota has reluctantly agreed to let me share the lovely poem she sent me yesterday, responding to my last two posts.  In it, Joyce puts into words what I’ve been trying to say for years: Pat, Someday, we won’t have to spend what precious time we have left on earth to pour through […]
  • After the obligatory 2 year waiting period following my approval to receive Social Security Disability (SSDI), I became eligible to receive Medicare.  I respectfully declined it.  Turns out my instinct were right! First, a comment.  Being forced to wait for medical coverage for two years when many patients need help NOW is wrong.  It’s just […]
  • A loyal reader recently asked me to participate in an off-the-cuff, impromptu experiment.  Justin had noticed that I had been having trouble with cramps at night.  An avid runner, apparently he’s often plagued by cramps, too. My cramping usually begins at 4 or 5 am, most always in my right calf and shin.  By now […]
  • Numbers don’t lie–except when they do.  I met with my medical oncologist, Dr. Mathew Luke yesterday.  That went fine.  Still too early to know if pomalidamide is working for me.  But I was devastated by my CBC results. Such a simple thing.  A complete blood count (CBC) measures the levels of red and white blood […]
  • By now I shouldn’t need to convince you that patient education is the cornerstone of living better and longer with multiple myeloma.  Access to audio and video interviews with leading myeloma specialists helps make it easy. Several times a month the clinical trial search engine, TrialX, sponsors Cure Talk broadcasts focusing on multiple myeloma.   I’m […]
  • Talk about conflicting data!   According to a number of researchers, the amino acid, L-glutamine, may be bad for multiple myeloma patients.  Yet taken in large enough doses it clearly helps many control their peripheral neuropathy. Danny Parker and I have warned our readers repeatedly about the risks of taking L-glutamine (most shorten it to “glutamine”) […]
  • [...]
  • Topping yesterday’s summary list of foods for multiple myeloma patients to avoid: excessively toasted breads and baked goods.  The process produces a acrylamide, a well known carcinogen.  For years myeloma specialists have told patients that diet has nothing to do with multiple myeloma.  This was still the prevailing view in 2012.  Danny Parker was ahead […]
  • Now that these broadcast have aired you can listen to the rebroadcast from Mayo Clinic's Dr. Shaji Kumar if you CLICK HERE.   Dr. Durie's rebroadcast is now available if you CLICK HERE [...]